Alexion Pharmaceuticals has announced that the FDA has approved Strensiq (asfotase alfa) for the treatment of patients with perinatal-, infantile-...
Alexion Pharmaceuticals, Inc. announced that the European Commission has approved Strensiq (asfotase alfa) for long-term enzyme replacement therapy in patients...
Alexion Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease (see section 5.1).
NICE has published draft guidance recommending the drug asfotase alfa (also called Strensiq and made by Alexion Pharma UK) for...
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life.
This clinical trial is being conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These...
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.